Contact Us | Directions | Referring a Patient

A leading comprehensive brain tumor program, using molecular diagnostic, gene expression analysis,
cutting edge clinical trials and advanced medical informatics to customize treatment plans for cancer patients.
 Latest Headlines
•Brain Tumor Cells Release Tiny Sacs Which Carry Information That May Guide Treatment (Medical News Today)
Tue, 18 Nov 2008 12:10:30 GMT
•Despite Brain Tumor, Kennedy Returns To The Hill (CBS 3 Philadelphia)
Mon, 17 Nov 2008 17:31:18 GMT
•"Tommy Fund": A Unique Brain Tumor/Cancer Research Fund (Business Wire via Yahoo! Finance)
Mon, 17 Nov 2008 13:45:00 GMT
•Tiny Sacs Released By Brain Tumor Cells Carry Information That May Guide Treatment (Science Daily)
Sun, 16 Nov 2008 20:29:06 GMT
•Tiny sacs released by brain tumor cells carry information that may guide treatment (EurekAlert!)
Sun, 16 Nov 2008 18:31:02 GMT
•Cell Phone/Brain Tumor Connection Remains Inconclusive But They Pose Neurological Health Risks (Medical News Today)
Sat, 15 Nov 2008 11:09:18 GMT
•Brain tumor awareness effort hits the floor (The Delaware Business Ledger)
Fri, 14 Nov 2008 18:11:28 GMT
•Sen. Kennedy returns to work after June surgery (Reuters via Yahoo! News)
Tue, 18 Nov 2008 05:30:44 GMT

* Headlines are from industry sponsored news wires, medical journals and established news organizations from around the world . Please consider the source of the content when viewing the story.
   
 
UCLA begins new Avastin Trials for Patients with grade IV GBM Tumor

UCLA Neuro-Oncology is sponsoring a Phase II trial which will further evalu­ate the safety and effectiveness of Avastin when taken alone or when taken in combination with Irinotecan a topoisomerase inhibitor. Irinotecan is also an FDA-approved drug for the treatment of certain other cancers that directly attacks and damages cancer cells. The study will also determine whether Avastin with or with­out Irinotecan can prevent or slow the growth of the tumor and lead to increase length of survival.

Improving clinical outcomes in glioblastoma brain tumors with genetic analysis

In this study, featured in the New England Journal of Medicine, glioblastomas patients who were treated with gefitinib or erlotinib, were found to be responsive to EGFR kinase inhibitors and strongly associated with coexpression by the tumor of EGFRvIII and PTEN.



UCLA Neuro-Oncology & SiliconMED Launch Online Tool Correlating Gene Expression Levels with Overall Survival of Brain Cancer Patients

Genomic analysis is a powerful new tool permitting unprecedented insights into how brain tumors form and has been enabled primarily through microarray technology. ProbeSetAnalyzer.com, a new web based tool, is aiming to help clinicians and researchers take the massive amount of data created by microarrays and better visualize gene expression levels and how they relate to the overall survival of brain cancer patients.

Most Popular
.  Clinical Trials
.  Probe Set Analyzer
.  Our Team
.  Brain Tumor Translational Resource
.  Art of the Brain
.  Personalized Medicine using Targeted Molecular Therapy
.  Online Giving
.  How our Glioblastoma Multiforme Patients Perform

Spring / Summer 2008
Breakthroughs
BM-3-2008


(18)F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: Initial experience.
Eur J Radiol.
PMID: 18511228

Safety of anticoagulation use and bevacizumab in patients with glioma.
Neuro Oncol
PMID: 18436627

Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas.
Neuro Oncology
PMID: 18356283

Time course of imaging changes of GBM during extended bevacizumab treatment
J Neurooncol.
PMID: 18389177

Phase II Pilot Study of Bevacizumab in Combination With Temozolomide and Regional Radiation Therapy for Up-Front Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Interim Analysis of Safety and Tolerability.
Int J Radiat Oncol Biol Phys
PMID: 18355978

All Information content hearof is designed for educational purposes only and is not for the purpose of rendering medical advice or professional services. The information provided should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. Any specific questions you may have regarding an individual's medical condition should be directed to the individual's primary care physician or other attending physician. In addition, if you have or suspect you may have a health problem, you should consult your health care provider.

Portions Copyright (Search, Chart, Content Publishing Tools, Photography, ProviderIQ) 1998-2008 SiliconMED North America

ProviderIQ is a registered trademark of SiliconMED North America and used by permission.

Copyright © 2008 UCLA Neuro-Oncology Program | Timothly Cloughesy MD; Director
All Rights Reserved.

[Content Published:11/18/2008 5:24:12 AM PST]